The Efficacy of Different doses of Ursodeoxycolic acid on Neonatal jaundic

Abstract

The aim of this study was to determine the effect of ursodeoxycholic acid (Ursobil) on the reduction of jaundice in newborns. Materials and Methods: The present study was carried out in a clinical trial and in 1396, the neonates were divided into three groups of 40 (phototherapy+ursobil 5mg/kg, phototherapy+ ursobil 7.5 mg/kg, and phototherapy groups). All stages of neonatal control were evaluated for hyperbilirubinemia and phototherapy and diarrhea or constipation, and complications such as nausea and oral intolerance, and the state of breastfeeding in all three groups were compared and compared. The amount of bilirubin was also checked 6,12, 24, 48 hours later. All newborns' information and questions asked from the parents of newborns, along with neonatal Bilirubin tests, were entered into a pre-designed checklist. Finally, all the data entered the SPSS v16 statistical analysis program and analyzed the data. Results: In this study, 120 infants with neonatal jaundice were divided into three groups: control (phototherapy), dose of 5 mg (phototherapy +5 mg/kg/dose of ursobil) and dose of 7.5 (phototherapy + 7.5 mg/kg/dose of ursobil). The mean age of neonates in the control group was 5.91 ± 2.49 days, in the 5 mg group 5.9 ± 2.62 days, and in the 7.5 mg group 5.1 ± 2.47 days. The majority of patients in all groups were boys. In this study, a higher dose of ursobil could significantly reduce the indirect bilirubin levels at post-hospital hours significantly. In spite of a decrease in bilirubin levels at a dose of 5 mg bilirubin, this drug was significantly decreased at a dose of 7.5 mg. It was also observed that a higher dose of ursobil could significantly reduce the duration of hospitalization in newborns. The duration of phototherapy also significantly decreased in recipients of ursobil.